| œ | GEM+CBDCA—Ö@ | |||||||
| œ | UC-Pembrolizumab | |||||||
| œ | ”A˜Hã”çŠà ÍßÑÌÞÛØ½ÏÌޗÖ@ 6TŠÔ»²¸Ù | |||||||
| œ | ”A˜Hã”çŠà ƒpƒhƒZƒu—Ö@ | |||||||
| œ | ”A˜Hã”çŠà ƒAƒxƒ‹ƒ}ƒuˆÛŽ—Ã–@ | |||||||
| œ | (‰ü’ù”Å)GC | |||||||
| œ | GEM+CBDCA—Ö@(30<CCr<60 CDDP•s‰ÂÇ—áj | |||||||
| œ | y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 2TŠÔƒTƒCƒNƒ‹ | |||||||
| œ | y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 4TŠÔƒTƒCƒNƒ‹ | |||||||
| @ | @ | |||||||
| @ | @ | @ | @ | @ | @ | @ | @ | @ |
| @ | @ | @ | @ | @ | @ | @ | @ | @ |
| @ | @ | @ | @ | @ | @ | @ | @ | @ |
| @ | @ | @ | @ | @ | @ | @ | @ | @ |
| @ | @ | @ | @ | @ | @ | @ | @ | @ |
| @ | @ | @ | @ | @ | @ | @ | @ | @ |